SKYCLARYS Biogen Australia Pty Ltd
Product name
SKYCLARYS
Sponsor
Accepted date
Jul-2024
Active ingredients
omaveloxolone
Proposed indication
For the treatment of Friedreich’s ataxia.
Application type
A (new medicine)
Publication date
Jul-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.